Syntonix, Biovitrum deal

Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) exercised an opt-in right from Biogen Idec Inc. (NASDAQ:BIIB, Weston, Mass.) to take over development and commercialization of Elocta to treat hemophilia A in Europe, North Africa, Russia and most Middle Eastern markets. Pending approval of Elocta, Swedish Orphan will pay Biogen Idec $10 million for exercising the right. Swedish Orphan will also reimburse Biogen Idec for costs incurred, which Swedish Orphan estimates to be about $240 million. Last month, EMA accepted for review an MAA for the long-acting recombinant fusion protein consisting of the Fc domain of human IgG1 attached to Factor VIII (see BioCentury, Jan. 30, 2006; Feb. 13, 2012 & Nov. 10, 2014). ...